Get the Stockscreener App
3.259
109.67%
1.709
Conduit Pharmaceuticals Inc stock is traded at $3.259, with a volume of 110.44M.
It is up +109.67% in the last 24 hours and down -65.43% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$1.55
Open:
$2.67
24h Volume:
110.44M
Relative Volume:
48.50
Market Cap:
$2.38M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-59.47
EPS:
-0.0548
Net Cash Flow:
-
1W Performance:
+31.04%
1M Performance:
-65.43%
6M Performance:
-80.30%
1Y Performance:
-98.81%
1-Day Range:
$2.25
$3.70
1-Week Range:
$1.45
$3.70
52-Week Range:
$1.45
$392.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
3.225 | 2.38M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.00 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.45 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.03 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.79 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Stock market today: Conduit Pharmaceuticals +83.87%, Doximity +31.02% among top gainers as more companies release their quarterly earnings - Business Upturn
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Conduit Pharmaceuticals Inc (CDT) requires closer examination - US Post News
Conduit Pharmaceuticals files to sell 5.9M shares of common stock for holders - MSN
Analysts review Conduit Pharmaceuticals Inc’s rating - Knox Daily
Closing Bell Recap: Conduit Pharmaceuticals Inc (CDT) Ends at 1.80, Reflecting a -18.18 Downturn - The Dwinnex
Conduit Pharmaceuticals Inc (CDT) vs. Its Peers: A Comparison - The News Heater
Short Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Declines By 67.6% - MarketBeat
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Quotes, Forecast and News Summary - Benzinga
Conduit Pharmaceuticals Inc (NASDAQ: CDT) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
Pre-Hour Trading Boosts Conduit (CDT) Following A Milestone - Stocks Telegraph
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence - The Manila Times
AI Breakthrough: How Conduit Pharma's Latest Tech Integration Could Revolutionize Drug Development Time - StockTitan
Stock market today: Nebius Group -30.94%, Conduit Pharmaceuticals -26.68% among biggest losers in early trading - Business Upturn
Conduit Pharmaceuticals to execute 1-for-100 reverse stock split - MSN
Conduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standards - MSN
Conduit Pharmaceuticals Implements Reverse Stock Split Plan - TipRanks
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - The Manila Times
Conduit Pharmaceuticals Announces 1-for-100 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan
Conduit Pharmaceuticals Enters Strategic Agreement with Agility Life Sciences - Contract Pharma
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline - The Manila Times
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for - The Bakersfield Californian
Conduit Pharma Partners with Agility Life Sciences to Advance Autoimmune Drug Formulations - StockTitan
Conduit Pharmaceuticals secures stockholder approval By Investing.com - Investing.com Australia
Conduit Pharmaceuticals secures stockholder approval - Investing.com
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Nasdaq Down Over 2%; Walgreens Posts Upbeat Results - Benzinga
Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December - Benzinga
Stock market today: IGM Biosciences plunged by 69.52% while XTI Aerospace down by 52.08% in early trading - Business Upturn
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today? - MSN
Presidio Property Trust Announces Series D Preferred Stock Cash Dividend - The Manila Times
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Conduit Pharmaceuticals faces Nasdaq delisting over price, votes for reverse split - Investing.com India
Stock Plummets to Cents. Can the Company Bounce Back? - Jomfruland.net
Conduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock Split - TipRanks
Vela Technologies reports loss amid portfolio challenges By Investing.com - Investing.com Nigeria
Conduit Pharmaceuticals Leverages AI for Drug Development - Nasdaq
Conduit and Sarborg link to optimise AI drug development - MSN
Conduit, Sarborg partner to optimise drug development through AI - Pharmaceutical Technology
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics - The Manila Times
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial - The Bakersfield Californian
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and - EIN News
Presidio Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule - The Manila Times
Conduit Pharmaceuticals files to sell 75M shares of common stock for holders - MSN
Conduit Pharmaceuticals issues convertible note, amends Nirland agreement - Investing.com
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Conduit Pharmaceuticals Inc Stock (CDT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nirland Ltd | 10% Owner |
Oct 04 '24 |
Sale |
0.10 |
1,368,991 |
140,458 |
7,031,009 |
| Nirland Ltd | 10% Owner |
Oct 07 '24 |
Sale |
0.10 |
939,009 |
96,530 |
6,092,000 |
| Nirland Ltd | 10% Owner |
Oct 01 '24 |
Sale |
0.11 |
1,250,000 |
141,375 |
10,233,177 |
| Nirland Ltd | 10% Owner |
Sep 30 '24 |
Sale |
0.12 |
1,016,823 |
122,019 |
11,483,177 |
| Nirland Ltd | 10% Owner |
Oct 02 '24 |
Sale |
0.10 |
333,177 |
34,251 |
9,900,000 |
| Regan Andrew | Director |
Jul 16 '24 |
Sale |
0.32 |
10,244,392 |
3,246,448 |
1,691,727 |
| Regan Andrew | Director |
Jul 17 '24 |
Sale |
0.26 |
1,514,100 |
391,092 |
177,627 |
| Regan Andrew | Director |
Jul 12 '24 |
Sale |
0.25 |
1,389,820 |
343,425 |
12,941,319 |
| Regan Andrew | Director |
Jul 11 '24 |
Sale |
0.29 |
882,952 |
260,253 |
14,331,139 |
| Regan Andrew | Director |
Jul 15 '24 |
Sale |
0.25 |
1,005,200 |
248,385 |
11,936,119 |
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):